Masimo Corp. (NASDAQ:MASI) reported preliminary 2025 results that landed at the high end of its guidance, signaling a successful first year under the leadership of Chief Executive Officer Katie Szyman.
Meta Platforms (NASDAQ:META) named Dina Powell McCormick as its new president and vice chairman on Monday, a major leadership pivot that brings a veteran of global finance and Republican politics into the center of the company’s multi-billion-dollar artificial intelligence expansion.
Shares in major U.S. lenders plummeted Monday morning after President Donald Trump blindsided the financial sector with a proposed 10% ceiling on credit card interest rates.
Amphenol Corp. (NYSE:APH) completed its acquisition of CommScope’s Connectivity and Cable Solutions (CCS) business on Monday, a transformational $10.5 billion deal that cements its position as a dominant provider of the hardware underpinning the artificial intelligence revolution.
Planet Fitness (NYSE:PLNT) reported a surge in year-end membership and same-club sales for 2025, signaling that its low-cost "Judgment Free Zone" model is continuing to capture market share among younger, budget-conscious consumers.
S&P Global (NYSE:SPGI) finalized the sale of its Enterprise Data Management (EDM) and thinkFolio businesses to private equity firm STG on Monday, concluding a divestiture aimed at sharpening the financial giant's focus on its core growth adjacencies.
Lipocine (NASDAQ:LPCN) experimental oral treatment for postpartum depression passed its final independent safety review, clearing the path for a critical data readout later this spring.
Hyperfine (NASDAQ:HYPR), the medical technology firm behind the first portable, AI-powered brain imaging system, reported a dramatic surge in fourth-quarter revenue, signaling a potential turning point for its bedside MRI technology.
Moderna (NASDAQ:MRNA) projected 2025 sales at the upper end of its forecast as a smaller-than-expected decline in U.S. vaccination rates and aggressive cost-cutting help the biotech giant navigate the post-pandemic landscape.
KORU Medical Systems (NASDAQ:KRMD) reported preliminary 2025 revenue that exceeded the high end of its guidance on Monday, as the medical technology firm prepares to pivot from its core immunology business into the high-growth oncology market.
Cellares and Cabaletta Bio (NASDAQ:CABA) announced a landmark regulatory achievement Monday, with the FDA clearing an Investigational New Drug (IND) Amendment to manufacture the autoimmune-focused CAR T therapy, rese-cel, using Cellares’ fully automated platforms.
GeneDx Holdings Corp. (NASDAQ:WGS) issued a bullish outlook for 2026 on Monday, forecasting revenue to exceed the half-billion-dollar milestone as the company’s pivot to high-margin exome and genome sequencing gains unprecedented traction.
